ACTRN12608000024347已完成2 期
To investigate the pharmacokinetics and pharmacodynamics of orally administered methadone-naloxone in a 50:1 ratio in partcipants who are opioid dependant and methadone maintained individuals aged between 18- 65
angton Centre0 个研究点目标入组 10 人开始时间: 2008年1月17日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Opioid dependent clients;
- •In treatment for greater than 2months
- •Stabilised on current dose for greater than 4 weeks
- •Willing to remain on current dose for duration of the trial
- •Venous access
- •Able to provide voluntary informed consent
排除标准
- •Considered unwilling, unable or unlikely to comply with the study protocol
- •Lactating and pregnant women
- •Active psychotic illness
研究者
相似试验
已完成
不适用
Clinical study to investigate the pharmacokinetics, efficacy, safety and immunogenicity of human-cl rhFVIII in previously treated patients with severe haemophilia ASevere haemophilia AHaematological DisordersHereditary factor VIII deficiencyISRCTN87293301Octapharma AG (Switzerland)20
进行中（未招募）
1 期
Study to Investigate the product Wilate in Patients with Severe Hemophilia ASevere hemophilia A (<1% FVIII:C)MedDRA version: 20.0Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2016-003681-34-PLOctapharma AG55
进行中（未招募）
1 期
Study to Investigate the product Wilate in Patients with Severe Hemophilia ASevere hemophilia A (<1% FVIII:C)MedDRA version: 20.0Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2016-003681-34-BGOctapharma AG55
进行中（未招募）
1 期
Study to Investigate the product Wilate in Patients with Severe Hemophilia ASevere hemophilia A (<1% FVIII:C)MedDRA version: 19.1Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2016-003681-34-HUOctapharma AG55
进行中（未招募）
不适用
To determine the pharmacokinetics of human-cl rhFVIII in terms of the FVIII coagulant activity (FVIII:C) and to compare it with the licensed FVIII concentrate Kogenate/Helixate in previously treated subjects suffering from severe hemophilia A.EUCTR2008-001563-11-BGOctapharma AG22